Humacyte Inc (NASDAQ:HUMA) shares, rose in value on Wednesday, March 26, with the stock price down by -30.43% to the previous day’s close as strong demand from buyers drove the stock to $2.00.
Actively observing the price movement in the last trading, the stock closed the session at $2.88, falling within a range of $1.96 and $2.17. The value of beta (5-year monthly) was 1.36. Referring to stock’s 52-week performance, its high was $9.97, and the low was $2.75. On the whole, HUMA has fluctuated by -34.21% over the past month.
With the market capitalization of Humacyte Inc currently standing at about $257.34 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-03.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HUMA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of HUMA currently trading nearly -34.50% and -46.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 27.20, while the 7-day volatility ratio is showing 8.62% which for the 30-day chart, stands at 9.59%. Furthermore, Humacyte Inc (HUMA)’s beta value is 1.40, and its average true range (ATR) is 0.34.
A comparison of Humacyte Inc (HUMA) with its peers suggests the former has fared considerably weaker in the market. HUMA showed an intraday change of -30.43% in last session, and over the past year, it shrunk by -39.58%%.
Data on historical trading for Humacyte Inc (NASDAQ:HUMA) indicates that the trading volumes over the past 10 days have averaged 2.24 and over the past 3 months, they’ve averaged 2.63 million. According to company’s latest data on outstanding shares, there are 119.84 million shares outstanding.
Nearly 18.87% of Humacyte Inc’s shares belong to company insiders and institutional investors own 33.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 26.6 million shares as on 2025-03-14, resulting in a short ratio of 11.69. According to the data, the short interest in Humacyte Inc (HUMA) stood at 2664.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 24.08 million. The stock has fallen by -60.40% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HUMA stock heading into the next quarter.
